Chih-Ku Liu
Overview
Explore the profile of Chih-Ku Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu T, Sun L, Shih Y, Chen Y, Fan C, Wang S, et al.
BMC Med
. 2025 Feb;
23(1):99.
PMID: 39984939
Background: Uterine serous carcinoma and carcinosarcoma are aggressive forms of endometrial cancer with poor survival outcomes. Trastuzumab, a human epidermal growth factor receptor-2 (HER2)-directed monoclonal antibody, has demonstrated tumoricidal efficacy....
2.
Liu C, Huang K, Chen M, Lu C, Hwang S, Sun L, et al.
Gynecol Minim Invasive Ther
. 2024 Mar;
13(1):4-9.
PMID: 38487609
Although the incidence of most cancers increases with age, a considerable number of patients receive a diagnosis of cancer during their reproductive years. Young women wishing to get pregnant after...
3.
Tsai C, Liu C, Yang E, Ying T, Chen G, Hung M
J Clin Med
. 2024 Jan;
13(2).
PMID: 38276143
Voiding dysfunction (VD) after sling operation is not uncommon. Sling revisions by incision/excision are usually effective; however, they may result in recurrent stress urinary incontinence (SUI). We aimed to evaluate...
4.
Chen Y, Hsu S, Hwang S, Sun L, Liu C, Shih Y, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256699
(1) Background: Our aim was to evaluate the efficacy and adverse effects of maintenance chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer after second-line chemotherapy. (2) Methods: A total of 72...
5.
Niu S, Sun L, Hsu S, Hwang S, Liu C, Shih Y, et al.
Front Oncol
. 2023 Dec;
13:1282596.
PMID: 38090488
Purpose: Uterine leiomyosarcoma is a rare and aggressive tumor known for its drug resistance and metastatic potential. The standard first-line treatment typically involves anthracycline-based chemotherapy or a combination of gemcitabine...
6.
Lin C, Liu C, Hsieh H, Chen M, Tsai C
Diagnostics (Basel)
. 2023 Sep;
13(18).
PMID: 37761358
(1) Background: Treating female pelvic organ prolapse (POP) is challenging. Surgical meshes have been used in transvaginal surgeries since the 1990s, but complications such as mesh exposure and infection have...
7.
Su Y, Su H, Liu C, Lu C, Hsu S
Cureus
. 2023 Jul;
15(6):e40481.
PMID: 37461790
Historically known as a "silent killer", ovarian cancer is often diagnosed at an advanced stage. We describe an unusual case of stage I, ovarian, high-grade serous carcinoma detected by a...
8.
Fan C, Hsu S, Sun L, Hwang S, Liu C, Shih Y, et al.
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675532
Tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic marker in endometrial cancer (EC). However, the role of TILs in EC with distinct histology grades and molecular types (such as mismatch...
9.
Lin C, Liu C, Hsieh H, Chen M, Tsai C
Diagnostics (Basel)
. 2022 Aug;
12(8).
PMID: 36010358
(1) Background: Limited data showed changes in glomerulation in the bladder mucosa of patients with interstitial cystitis (IC) after intravesical hyaluronic acid (HA) bladder infusion. We aimed to investigate the...
10.
Hung J, Hsu S, Sun L, Hwang S, Liu C, Shih Y, et al.
Front Oncol
. 2022 Jun;
12:843278.
PMID: 35664738
Background: Bevacizumab in combination with chemotherapy prolonged the progression-free survival (PFS) of patients with recurrent epithelial ovarian cancer (EOC) in large-scale randomized controlled trials. However, real-world data for the use...